With so many shares to choose from on the Australian share market, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.
Three top ASX shares that leading brokers have named as buys this week are listed below. Here's why they are bullish on them:
Image source: Getty Images
Elders Ltd (ASX: ELD)
According to a note out of Macquarie, its analysts have retained their outperform rating on this agribusiness company's shares with an improved price target of $8.40. This follows the release of Elders' investor update, which revealed that its performance was improving as conditions normalise. Looking ahead, Macquarie believes the company is well-placed for growth over the medium term as it realises synergies from the Delta Agribusiness acquisition. In light of this, the broker sees value in the company's shares at current levels. The Elders share price is trading at $7.61 on Monday afternoon.
Genesis Minerals Ltd (ASX: GMD)
A note out of Bell Potter reveals that its analysts have retained their buy rating on this gold miner's shares with an improved price target of $9.90. The broker highlights that Genesis Minerals delivered a strong second quarter update, with record-breaking production coming in ahead of expectations. Bell Potter believes there is more to come in the second half. So much so, it expects the company to achieve the upper end of its production guidance in FY 2026. In addition, the broker points out that it likes Genesis Minerals due to its belief that it is a high-quality gold producer that is expanding production in a rising gold price environment. The Genesis Minerals share price is fetching $6.98 at the time of writing.
ResMed Inc. (ASX: RMD)
Analysts at Morgans have upgraded this sleep disorder treatment company's shares to a buy rating with a $47.73 price target. According to the note, Morgans was pleased with ResMed's performance in the second quarter. It highlights that the result was a beat across the board, with double-digit revenue and earnings growth, further gross margin expansion, and solid cash generation. ResMed's operating leverage has seen the broker lift its earnings estimates and valuation slightly. And with its shares down unjustifiably and materially from recent highs, Morgans thinks now is a good time to invest. The ResMed share price is trading at $36.74 this afternoon.
